Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Israel-based Pluristem Therapeutics has collaborated with the BIH Center for Regenerative Therapy (BCRT) and the Berlin Center for Advanced Therapies (BeCAT) at Charite’ University of Medicine Berlin to work on Covid-19 therapies.

The partnership will see a joint project to explore Pluristem’s PLX cell product candidates for treating respiratory and inflammatory complications caused by the novel coronavirus infection.

PLX cells trigger the immune system’s regulatory T-cells and M2 macrophages, expected to help reduce fatal pneumonia and pneumonitis symptoms induced by Covid-19.

In prior preclinical studies, PLX cells showed significant therapeutic effects against pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury in animal models.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These health conditions are considered potential complications of severe Covid-19 infection.

Pluristem Therapeutics president and CEO Yaky Yanay said: “The collaboration with Charité researchers will allow us to expedite our program to potentially enable the use of PLX cells to treat patients infected with COVID-19 that have respiratory and immunological complications.

“The fact that PLX is available off-the-shelf, combined with our ability to manufacture large scale quantities, is a key advantage in case a large number of patients may need respiratory support.

“The primary target is to prevent the deterioration of patients towards Acute Respiratory Distress Syndrome (ARDS) and sepsis.”